Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

AVALO THERAPEUTICS, INC.

cerecor.com
Filed: Jun 23, 2026WayneCIK: 0001534120Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Avalo Therapeutics appointed Ron Philip to its Board of Directors effective June 23, 2026, with committee assignments to the Compensation Committee and Science, Development and Commercial Advisory Committee, enhancing the company's governance structure.

Key Takeaways

Ron Philip appointed as director, serving until the 2027 Annual Meeting of Stockholders

Philip assigned to both Compensation Committee and Science, Development and Commercial Advisory Committee

2 more takeaways

Related Filings (2)

2 more filings from AVALO THERAPEUTICS, INC. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJun 23, 2026
Item5.02
CategoryExecutive Change
CIK0001534120
Accession #avtx-20260623
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings